

Gianmarco Abbadessa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1874598/publications.pdf>

Version: 2024-02-01

94
papers

2,254
citations

186265

28
h-index

276875

41
g-index

99
all docs

99
docs citations

99
times ranked

3179
citing authors

#	ARTICLE	IF	CITATIONS
1	Digital therapeutics in neurology. <i>Journal of Neurology</i> , 2022, 269, 1209-1224.	3.6	58
2	Disability assessment using Google Maps. <i>Neurological Sciences</i> , 2022, 43, 1007-1014.	1.9	10
3	SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1034-1040.	3.0	37
4	Hemostatic factors in the pathogenesis of neuroinflammation in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1834-1842.	3.0	5
5	Multiple sclerosis and genetic polymorphisms in fibrinogen-mediated hemostatic pathways: a case-control study. <i>Neurological Sciences</i> , 2022, 43, 2601-2609.	1.9	5
6	The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis. <i>European Journal of Neurology</i> , 2022, 29, 535-542.	3.3	8
7	Pain, quality of life, and religiosity in people with multiple sclerosis. <i>Neurological Sciences</i> , 2022, 43, 3247-3254.	1.9	5
8	Hemostasis Components as Therapeutic Targets in Autoimmune Demyelination. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 807-816.	4.7	2
9	Telemedicine application to headache: a critical review. <i>Neurological Sciences</i> , 2022, 43, 3795-3801.	1.9	13
10	Association between relapses, stress, and depression in people with multiple sclerosis during the COVID-19 pandemic. <i>Neurological Sciences</i> , 2022, 43, 2935-2942.	1.9	6
11	Family planning in people with multiple sclerosis: a plain language summary. <i>Neurodegenerative Disease Management</i> , 2022, 12, 9-14.	2.2	2
12	Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 2081.	2.4	6
13	Lymphopenia in Multiple Sclerosis patients treated with Ocrelizumab is associated with an effect on CD8 T cells. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 60, 103740.	2.0	10
14	Support Needs and Interventions for Family Caregivers of Patients with Amyotrophic Lateral Sclerosis (ALS): A Narrative Review with Report of Telemedicine Experiences at the Time of COVID-19 Pandemic. <i>Brain Sciences</i> , 2022, 12, 49.	2.3	14
15	Optimal retreatment schedule of rituximab for neuromyelitis optica spectrum disorder: A systematic review. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103926.	2.0	5
16	Emotional facial palsy: an unusual and rarely explored neurological sign. <i>Neurological Sciences</i> , 2022, 43, 6305-6307.	1.9	2
17	Hippocampal connectivity in Amyotrophic Lateral Sclerosis (ALS): more than Papez circuit impairment. <i>Brain Imaging and Behavior</i> , 2021, 15, 2126-2138.	2.1	18
18	Psychiatric disorders in multiple sclerosis. <i>Journal of Neurology</i> , 2021, 268, 45-60.	3.6	30

#	ARTICLE	IF	CITATIONS
19	Lifestyle and Mediterranean diet adherence in a cohort of Southern Italian patients with Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 47, 102636.	2.0	29
20	Unilateral polymicrogyria, hemispheric atrophy and spastic hemiparesis: rare etiologies for a common condition. <i>Acta Neurologica Belgica</i> , 2021, 121, 789-790.	1.1	0
21	Telemedicine for management of patients with amyotrophic lateral sclerosis through COVID-19 tail. <i>Neurological Sciences</i> , 2021, 42, 9-13.	1.9	43
22	Resting state functional MRI brain signatures of fast disease progression in amyotrophic lateral sclerosis: a retrospective study. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, 22, 117-126.	1.7	10
23	Coping strategies in relapsing/remitting multiple sclerosis non-depressed patients and their associations with disease activity. <i>Acta Neurologica Belgica</i> , 2021, 121, 465-471.	1.1	13
24	Digital work engagement among Italian neurologists. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232110296.	2.5	7
25	Paraneoplastic syndrome or immune-related adverse event? A case of rhomboencephalitis in a patient treated with Pembrolizumab. <i>Acta Neurologica Belgica</i> , 2021, 121, 1341-1342.	1.1	1
26	Stroke and digital technology: a wake-up call from COVID-19 pandemic. <i>Neurological Sciences</i> , 2021, 42, 805-809.	1.9	28
27	Perceived stress and social support in a large population of people with multiple sclerosis recruited online through the COVID-19 pandemic. <i>European Journal of Neurology</i> , 2021, 28, 3396-3402.	3.3	36
28	Public Engagement and Neurology: An Update. <i>Brain Sciences</i> , 2021, 11, 429.	2.3	5
29	Physical Exercise Moderates the Effects of Disability on Depression in People with Multiple Sclerosis during the COVID-19 Outbreak. <i>Journal of Clinical Medicine</i> , 2021, 10, 1234.	2.4	10
30	Assessment of Multiple Sclerosis Disability Progression Using a Wearable Biosensor: A Pilot Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 1160.	2.4	25
31	Family Planning Decision Making in People With Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2021, 12, 620772.	2.4	16
32	Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study. <i>Neurotherapeutics</i> , 2021, 18, 1166-1174.	4.4	24
33	Digital Technology in Clinical Trials for Multiple Sclerosis: Systematic Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 2328.	2.4	19
34	MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study. <i>Journal of the Neurological Sciences</i> , 2021, 424, 117385.	0.6	9
35	How to manage with telemedicine people with neuromuscular diseases?. <i>Neurological Sciences</i> , 2021, 42, 3553-3559.	1.9	23
36	Family Functioning and Multiple Sclerosis: Study Protocol of a Multicentric Italian Project. <i>Frontiers in Psychology</i> , 2021, 12, 668010.	2.1	2

#	ARTICLE	IF	CITATIONS
37	Understanding and managing the impact of the Covid-19 pandemic and lockdown on patients with multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 731-743.	2.8	10
38	DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1738-1744.	3.7	86
39	Myasthenia gravis and telemedicine: a lesson from COVID-19 pandemic. <i>Neurological Sciences</i> , 2021, 42, 4889-4892.	1.9	21
40	CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8163.	2.6	10
41	Digital work engagement among Italian neurologists. <i>Journal of the Neurological Sciences</i> , 2021, 429, 117863.	0.6	1
42	Vitamin D levels influence radiological and laboratory outcomes of multiple sclerosis patients treated with Ocrelizumab. <i>Journal of the Neurological Sciences</i> , 2021, 429, 118087.	0.6	0
43	Ocrelizumab modifies circulating immune asset in relapsing-remitting multiple sclerosis subjects. <i>Journal of the Neurological Sciences</i> , 2021, 429, 118820.	0.6	0
44	Source of medical information and behavioral seeking patterns in patients affected with Friedreich's ataxia and their caregivers: a survey study. <i>Neurological Sciences</i> , 2021, , 1.	1.9	1
45	Vitamin D supplementation has no effects on progression of motor dysfunction in amyotrophic lateral sclerosis (ALS). <i>European Journal of Clinical Nutrition</i> , 2020, 74, 167-175.	2.9	19
46	Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1519-1531.	3.0	38
47	Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?. <i>Neurotherapeutics</i> , 2020, 17, 200-207.	4.4	39
48	COVID-19 pandemic and mental distress in multiple sclerosis: implications for clinical management. <i>European Journal of Neurology</i> , 2020, 28, 3375-3383.	3.3	47
49	Telemedicine in Parkinson's Disease: How to Ensure Patient Needs and Continuity of Care at the Time of COVID-19 Pandemic. <i>Telemedicine Journal and E-Health</i> , 2020, 26, 1533-1536.	2.8	55
50	Ocrelizumab in a case of refractory chronic inflammatory demyelinating polyneuropathy with anti-rituximab antibodies. <i>European Journal of Neurology</i> , 2020, 27, 2673-2675.	3.3	14
51	Telemedicine and the challenge of epilepsy management at the time of COVID-19 pandemic. <i>Epilepsy and Behavior</i> , 2020, 110, 107164.	1.7	49
52	A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting. <i>Neurological Sciences</i> , 2020, 41, 3235-3241.	1.9	9
53	Online Validation of a Battery of Questionnaires for the Assessment of Family Functioning and Related Factors. <i>Frontiers in Psychology</i> , 2020, 11, 771.	2.1	5
54	BMI influences CD20 kinetics in multiple sclerosis patients treated with ocrelizumab. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 43, 102186.	2.0	25

#	ARTICLE	IF	CITATIONS
55	Readability Analysis of Online Headache and Migraine Information. <i>Headache</i> , 2020, 60, 1317-1324.	3.9	7
56	Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis. <i>Journal of Neurology</i> , 2020, 267, 3008-3020.	3.6	19
57	Dementia care and COVID-19 pandemic: a necessary digital revolution. <i>Neurological Sciences</i> , 2020, 41, 1977-1979.	1.9	142
58	First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102059.	2.0	4
59	The Use of Social Media and Digital Devices Among Italian Neurologists. <i>Frontiers in Neurology</i> , 2020, 11, 583.	2.4	18
60	Is antibody titer useful to verify the immunization after VZV Vaccine in MS patients treated with Fingolimod? A case series. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 40, 101963.	2.0	14
61	Digital triage for people with multiple sclerosis in the age of COVID-19 pandemic. <i>Neurological Sciences</i> , 2020, 41, 1007-1009.	1.9	48
62	Assessing disability and relapses in multiple sclerosis on tele-neurology. <i>Neurological Sciences</i> , 2020, 41, 1369-1371.	1.9	65
63	Heidenhain variant of Creutzfeldt-Jakob disease in a patient carrying the V210I mutation with asymmetric MRI abnormalities. <i>Acta Neurologica Belgica</i> , 2020, 120, 1007-1009.	1.1	2
64	Atypical progressive multifocal leukoencephalopathy in a kidney transplant recipient with improving symptoms after immunocompetence recovery. <i>Infezioni in Medicina</i> , 2020, 28, 87-90.	1.1	1
65	Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1263-1272.	3.0	36
66	Gait abnormalities in minimally disabled people with Multiple Sclerosis: A 3D-motion analysis study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 29, 100-107.	2.0	42
67	Right phrenic nerve palsy following transcatheter radiofrequency current atrial fibrillation ablation: Case report. <i>Journal of International Medical Research</i> , 2019, 47, 3438-3443.	1.0	2
68	Impact of early diagnosis on clinical characteristics of an Italian sample of people with multiple sclerosis recruited online. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 239-246.	2.0	9
69	Factors interfering with parenthood decision-making in an Italian sample of people with multiple sclerosis: an exploratory online survey. <i>Journal of Neurology</i> , 2019, 266, 707-716.	3.6	14
70	Online validation of the Italian version of the patient determined disease steps scale (PDDS) in people with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 21, 108-109.	2.0	11
71	Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria. <i>Journal of Neurology</i> , 2018, 265, 828-835.	3.6	45
72	A simple measure of cognitive reserve is relevant for cognitive performance in MS patients. <i>Neurological Sciences</i> , 2018, 39, 1267-1273.	1.9	8

#	ARTICLE	IF	CITATIONS
73	Neurology and the Internet: a review. <i>Neurological Sciences</i> , 2018, 39, 981-987.	1.9	36
74	The Role of Wearable Devices in Multiple Sclerosis. <i>Multiple Sclerosis International</i> , 2018, 2018, 1-7.	0.8	32
75	e-Health and multiple sclerosis: An update. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1657-1664.	3.0	63
76	Cognitive performance in multiple sclerosis: the contribution of intellectual enrichment and brain MRI measures. <i>Journal of Neurology</i> , 2018, 265, 1772-1779.	3.6	14
77	Fake news, influencers and health-related professional participation on the Web: A pilot study on a social-network of people with Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 175-178.	2.0	49
78	Health-care disparities stemming from sexual orientation of Italian patients with Multiple Sclerosis: A cross-sectional web-based study. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 13, 28-32.	2.0	21
79	Validity and reproducibility of the Italian version of the patient determined disease steps scale in people with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 18, 173-176.	2.0	21
80	A disease in the age of the web: How to help people with Multiple Sclerosis in social media interaction. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 17, 238-239.	2.0	8
81	Default mode network changes in multiple sclerosis: a link between depression and cognitive impairment?. <i>European Journal of Neurology</i> , 2017, 24, 27-36.	3.3	44
82	Health-Related Coping and Social Interaction in People with Multiple Sclerosis Supported by a Social Network: Pilot Study With a New Methodological Approach. <i>Interactive Journal of Medical Research</i> , 2017, 6, e10.	1.4	36
83	Social Media and Multiple Sclerosis in the Posttruth Age. <i>Interactive Journal of Medical Research</i> , 2017, 6, e18.	1.4	22
84	Depressive Symptoms Correlate with Disability and Disease Course in Multiple Sclerosis Patients: An Italian Multi-Center Study Using the Beck Depression Inventory. <i>PLoS ONE</i> , 2016, 11, e0160261.	2.5	46
85	Theory of Mind and Its Neuropsychological and Quality of Life Correlates in the Early Stages of Amyotrophic Lateral Sclerosis. <i>Frontiers in Psychology</i> , 2016, 7, 1934.	2.1	25
86	The Dress: Transforming a web viral event into a scientific survey. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 7, 41-46.	2.0	16
87	Dilated perivascular spaces and fatigue: is there a link? Magnetic resonance retrospective 3Tesla study. <i>Neuroradiology</i> , 2016, 58, 859-866.	2.2	15
88	Anxiety in Multiple Sclerosis: psychometric properties of the State-Trait Anxiety Inventory. <i>Acta Neurologica Scandinavica</i> , 2016, 134, 458-466.	2.1	43
89	Treatment withdrawal in relapsing~remitting multiple sclerosis: a retrospective cohort study. <i>European Journal of Neurology</i> , 2016, 23, 489-493.	3.3	8
90	Psychometric properties and validity of Beck Depression Inventory II in multiple sclerosis. <i>European Journal of Neurology</i> , 2016, 23, 744-750.	3.3	106

#	ARTICLE	IF	CITATIONS
91	Abnormal Connectivity Within Executive Restingâ€State Network in Migraine With Aura. <i>Headache</i> , 2015, 55, 794-805.	3.9	69
92	Lesion Load May Predict Long-Term Cognitive Dysfunction in Multiple Sclerosis Patients. <i>PLoS ONE</i> , 2015, 10, e0120754.	2.5	31
93	Computer-aided cognitive rehabilitation improves cognitive performances and induces brain functional connectivity changes in relapsing remitting multiple sclerosis patients: an exploratory study. <i>Journal of Neurology</i> , 2015, 262, 91-100.	3.6	93
94	Progressive multifocal leukoencephalopathy presenting with bilateral myoclonus: a case report. <i>Mediterranean Journal of Infection, Microbes and Antimicrobials</i> , 0, , .	0.2	0